Novo Nordisk, the Danish pharmaceutical giant, saw its shares fall by 7% despite setting a $23 billion sales target for its weight-loss drug.
Novo Nordisk's share price fell by as much as 7% on Monday after the company unveiled new growth ambitions aimed at reinvigorating its position in the booming obesity drug market. The company plans to launch more than five drugs with "multiple blockbuster" potential by 2030 and expects to achieve over DKK 150 billion (approximately $23 billion) in R&D pipeline sales by 2035. Additionally, Novo Nordisk anticipates revenue growth from 2026 to 2030 to be in line with industry peers.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Source:CNBC头条 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
PAYT Coin Historical Price Review and PayAccept Project Outlook Analysis
-
2
Securing Binance Assets: A Guide to Cold Wallets, MetaMask, and the BNB Chain Ecosystem
-
3
Central Bank Digital Currency (CBDC) In-Depth Analysis: Global Progress and Impact
-
4
OKX App Download Guide: Get the World's Leading Cryptocurrency Trading Platform Application
-
5
Ankr (ANKR) Token Analysis: Web3 Infrastructure, Ecosystem Applications, and Market Dynamics
-
6
US equity futures rise, led by AI stocks; oil prices fall over 2% to around $101; US Treasury yields decline; US and Chinese officials discuss AI national security "notification mechanism."
-
7
Gamium (GMM) Token Analysis: Value, Ecosystem, and Investment Risk Assessment
-
8
BiblePay (BBP) Cryptocurrency Analysis: Charitable Mission, Technical Features, and Market Status
-
9
XRP is testing the $1.50 resistance level, a key threshold that has capped its advances for roughly 230 days, with a break potentially leading to $1.80+
-
10
Seoul stocks rise 1.65% on chip gains despite Middle East tensions
Markets Today
Recommended Reading









